rs964184 — ZNF259 ZNF259/BUD13 Triglyceride Variant

Common regulatory variant at the APOA5-ZNF259 locus; G allele reduces ApoAV protein levels, impairing triglyceride clearance and raising plasma TG by ~13% per allele — one of the strongest common GWAS signals for triglycerides

See your personal result for ZNF259

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ZNF259/APOA5 — The Triglyceride Control Locus

At chromosome 11q23.3 sits a tightly packed cluster of lipid-metabolism genes — APOA5, APOA4, APOC3, and APOA1 — flanked by ZNF259 (also known as ZPR1) and BUD13. The rs964184 variant lies in the 3' untranslated region of ZNF259, but its most important effect is on the neighboring APOA5 gene, which encodes apolipoprotein AV11 apolipoprotein AV
ApoAV is a secreted protein produced mainly in the liver that activates lipoprotein lipase, the enzyme that breaks down triglyceride-rich particles in the bloodstream. G allele carriers produce less ApoAV protein after meals, impairing the clearance of triglyceride-carrying particles from circulation.

The Mechanism

rs964184 is a 3'UTR regulatory variant in ZNF259. Although its precise molecular mechanism is not fully resolved, functional studies have established a direct link between rs964184 genotype and postprandial ApoAV protein levels22 a direct link between rs964184 genotype and postprandial ApoAV protein levels
Weissglas-Volkov et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet, 2013. The G allele reduces ApoAV availability, which in turn impairs lipoprotein lipase activation — the rate- limiting step in clearing very-low-density lipoprotein (VLDL) triglycerides from the blood. This effect is dose-dependent: heterozygotes (CG) show intermediate triglyceride levels, while G;G homozygotes show the highest elevations.

The Evidence

rs964184 is one of the most replicated triglyceride-associated variants in the human genome, with genome-wide significant associations across European, East Asian, South Asian, African, and Latin American populations.

A large study of 5,547 patients with established vascular disease33 large study of 5,547 patients with established vascular disease
van de Woestijne et al. Rs964184 is related to elevated plasma triglyceride levels but not to an increased risk for vascular events. PLoS One, 2014 found each G allele adds approximately 0.12 log-units to fasting triglycerides (p=1.1×10⁻¹⁹), a substantial effect for a common variant. The G allele minor allele frequency rose from 10.9% in patients with the lowest triglycerides (<1 mmol/L) to 24.6% in those with the highest (4–10 mmol/L). Metabolic syndrome prevalence was 52% in CC homozygotes vs 62% in GG homozygotes.

A cross-ethnic fine-mapping study44 cross-ethnic fine-mapping study
Weissglas-Volkov et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet, 2013 narrowed the APOA5 locus signal to rs964184 as the single most likely causal variant underlying both European and Mexican GWAS signals, and demonstrated its functional link to postprandial ApoAV protein levels.

In an Iranian case-control study of metabolic syndrome, Mirhafez et al.55 Mirhafez et al.
Mirhafez et al. ZNF259 Gene Polymorphism rs964184 is Associated with Serum Triglyceride Levels and Metabolic Syndrome. Int J Mol Cell Med, 2016 found CG+GG genotypes conferred OR 2.52 (95%CI 1.33–4.77, p=0.005) for metabolic syndrome and elevated TG and LDL-C compared to wild-type CC.

A dietary intervention trial66 dietary intervention trial
Zhang et al. APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet. Am J Clin Nutr, 2012 found that G allele carriers showed greater reductions in LDL cholesterol on a long-term low-fat diet (20% fat), supporting genotype-specific dietary guidance.

Practical Actions

The key lever for G allele carriers is dietary fat composition and overall caloric pattern. Saturated fat drives VLDL-TG production independently of ApoAV, so reducing saturated fat intake directly lowers the TG burden that the impaired clearance pathway must handle. Fish-derived omega-3s (EPA/DHA) suppress hepatic TG synthesis via PPAR-alpha activation, providing a separate route to lower fasting and postprandial TG. Fasting TG monitoring every 12 months helps track whether dietary changes are taking effect, since fasting TG above 1.7 mmol/L (150 mg/dL) is a metabolic syndrome criterion and predicts cardiovascular risk.

Interactions

rs964184 sits in the same linkage disequilibrium block as several other triglyceride-associated variants at the APOA5 locus, including rs3135506 (APOA5 S19W missense) and rs662799 (APOA5 -1131T>C promoter). Carrying risk alleles at multiple positions in this cluster produces additive triglyceride elevation. The APOC3 variants rs2854116 and rs2854117 (also on chromosome 11) affect the same triglyceride clearance pathway through a different mechanism (ApoC-III-mediated inhibition of lipoprotein lipase) — users carrying risk alleles at both rs964184 and APOC3 variants face compounded impairment of TG clearance.

Nutrient Interactions

saturated fat altered_metabolism
omega-3 fatty acids increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal TG Clearance Normal

Common genotype — normal triglyceride clearance through APOA5 pathway

You carry two copies of the common C allele at rs964184, the most frequent genotype at this locus. About 66% of people globally share this genotype (around 77% of Europeans). Your ZNF259/APOA5 pathway produces normal amounts of apolipoprotein AV after meals, supporting efficient clearance of triglyceride-rich particles from the bloodstream.

CG Intermediate TG Risk Intermediate

One G allele — mildly elevated triglyceride risk via reduced ApoAV

The effect of the CG genotype on triglycerides is additive — one G allele produces an intermediate phenotype between the very common CC (normal) and the rarer GG (high-risk). The triglyceride elevation from this variant interacts with dietary saturated fat intake: a high-saturated-fat diet compounds the impairment in postprandial clearance, while a lower-fat diet attenuates the genetic effect. Dietary omega-3 fatty acids (EPA/DHA) suppress hepatic VLDL-TG production via a distinct pathway, providing an additional intervention route.

GG Elevated TG Risk High Risk

Two G alleles — significantly elevated triglycerides; proactive dietary management needed

The GG genotype represents the high end of the additive dose-response for rs964184. Fasting triglycerides in GG individuals are substantially higher than in CC carriers — the β of 0.12 log-units per G allele from the van de Woestijne study (PMID 24979386) predicts approximately 27% higher absolute fasting TG in GG versus CC on average. In the Mirhafez metabolic syndrome study (PMID 27386434), carrying G alleles conferred OR 2.52 for metabolic syndrome.

The dietary effect is particularly pronounced in GG carriers: saturated fat substantially amplifies TG elevation in APOA5 risk allele carriers, and conversely, a low-fat diet produces greater TG improvement in G allele carriers than in CC homozygotes (PMID 22914552). This makes dietary fat composition a high-leverage intervention specifically for this genotype.

Persistently elevated fasting TG above 2.3 mmol/L (200 mg/dL) warrants clinical evaluation; levels above 5.6 mmol/L (500 mg/dL) carry risk of pancreatitis. For GG carriers who cannot achieve adequate TG control through diet alone, fibrates or prescription omega-3 agents are established medical options.